Pharmacokinetics and biodistribution of novel aptamer compositions

Pharmaceutical Research

Volumn 21, Issue 12, 2004, Pages 2234-2246

  Healy, Judith M ^a   Lewis, Scott D ^a   Kurz, Markus ^a   Boomer, Ryan M ^a   Thompson, Kristin M ^a   Wilson, Charles ^a   McCauley, Thomas G ^a  

^a Archemix Corporation   (United States)

Author keywords

Aptamer; Biodistribution; Conjugation; Pharmacokinetics

Indexed keywords

APTAMER; ARC 120; ARC 122; ARC 155; ARC 156; ARC 157; ARC 158; ARC 159; ARC 83; MACROGOL; OLIGONUCLEOTIDE; POLYNUCLEOTIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG URINE LEVEL; MALE; MEAN RESIDENCE TIME; METHYLATION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OLIGONUCLEOTIDES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 17644399512     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-7676-4     Document Type: Article

References (46)

1. A. D. Ellington and J. W. Szostak. In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-22 (1990).
2. C. Tuerk and L. Gold. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510 (1990).
3. R. D. Jenison, S. D. Jennings, D. W. Walker, R. F. Bargatze, and D. Parma. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 8: 265-79 (1998).
4. L. C. Griffin, J. J. Toole, and L. L. Leung. The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene 137: 25-31 (1993).
5. S. R. Watson, Y. F. Chang, D. O'Connell, L. Weigand, S. Ringquist, and D. H. Parma. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev 10: 63-75 (2000).
6. M. Khati, M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon, and W. James. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 77: 12692-8 (2003).
7. C. H. Chen. G. A. Chernis. V. Q. Hoang, and R. Landgraf. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A 100: 9226-31 (2003).
8. N. K. Vaish, R. Larralde, A. W. Fraley, J. W. Szostak, and L. W. McLaughlin. A novel, modification-dependent ATP-binding aptamer selected from an RNA library incorporating a cationic functionality. Biochemistry 42: 8842-51 (2003).
9. D. A. Daniels, A. K. Sohal, S. Rees, and R. Grisshammer. Generation of RNA aptamers to the G-protein-coupled receptor for neurotensin. NTS-1. Anal Biochem 305: 214-26 (2002).
10. C. Bell, E. Lynam, D. J. Landfair, N. Janjic, and M. E. Wiles. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35: 533-42 (1999).
11. B. Wlotzka, S. Leva, B. Eschgfaller, J. Burmeister, F. Kleinjung, C. Kaduk, P. Muhn, H. Hess-Stumpp, and S. Klussmann. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A 99: 8898-902 (2002).
12. L. Reyderman and S. Stavchansky. Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats. Pharmaceutical Research 15: 904-10 (1998).
13. C. E. Tucker, L. S. Chen, M. B. Judkins, J. A. Farmer, S. C. Gill, and D. W. Drolet. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. 732: 203-12 (1999).
14. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYEOOl) for the treatment of exudative age-related macular degeneration. Retina 22: 143-52 (2002).
15. K. G. Carrasquillo, J. A. Ricker, I. K. Rigas, J. W. Miller, E. S. Gragoudas, and A. P. Adamis. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 44: 290-9 (2003).
16. L. S. Green, D. Jellinek, C. Bell, L. A. Beebe, B. D. Feistner, S. C. Gill, F. M. Jucker, and N. Janjic. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2: 683-95 (1995).
17. D. Jellinek, L. S. Green, C. Bell, C. K. Lynott, N. Gill, C. Vargeese, G. Kirschenheuter, D. P. McGee, P. Abesinghe, W. A. Pieken, and et al. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34: 11363-72 (1995).
18. J. Ruckman, L. S. Green, J. Beeson, S. Waugh, W. L. Gillette, D. D. Henninger, L. Claesson-Welsh, and N. Janjic. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273: 20556-67 (1998).
19. E. Uhlmann, A. Peyman, A. Ryte, A. Schmidt, and E. Buddecke. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol 313: 268-84 (2000).
20. P. E. Burmeister, S.D. Lewis, R.F. Silva, J.R. Preiss, L.R. Horwitz, P.S. Pendergrast, T.G. McCauley, J. C. Kurz, D. M. Epstein, C. Wilson, and A. D. Keefe. Direct In Vitro Selection of a 2′-O-Methyl-Stabilized Aptamer Against VEGF. Chem Biol, in press (2004).
21. J. Chelliserrykattil and A. D. Ellington. Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22: 1155-60 (2004).
22. S. Agrawal and R. Zhang. Pharmacokinetics of oligonucleotides. Ciba Found Symp 209: 60-75: discussion 75-8 (1997).
23. S. Akhtarand S. Agrawal. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 18: 12-8 (1997).
24. S. T. Crooke. Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv Pharmacol 40:1-49 (1997).
25. J. M. Grindel, T. J. Musick, Z. Jiang, A. Roskey, and S. Agrawal. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev 8: 43-52 (1998).
26. D. K. Monteith and A. A. Levin. Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 27: 8-13 (1999).
27. B. Peng, J. Andrews, I. Nestorov, B. Brennan, P. Nicklin, and M. Rowland. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev 11: 15-27 (2001).
28. S. K. Srinivasan and P. Iversen. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9: 129-37 (1995).
29. I. Lebedeva, L. Benimetskaya, C. A. Stein, and M. Vilenchik. Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 50: 101-19 (2000).
30. M. Antopolsky, E. Azhayeva, U. Tengvall, S. Auriola, I. Jaaskelainen, S. Ronkko, P. Honkakoski, A. Urtti, H. Lonnberg, and A. Azhayev. Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties. Bioconjug Chem 10: 598-606 (1999).
31. A. Astriab-Fisher, D. S. Sergueev, M. Fisher, B. R. Shaw, and R. L. Juliano. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol 60: 83-90 (2000).
32. M. Manoharan. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev 12: 103-28 (2002).
33. E. M. Zubin, E. A. Romanova, E. M. Volkov, V. N. Tashlitsky, G. A. Korshunova, Z. A. Shabarova, and T. S. Oretskaya. Oligonucleotide-peptide conjugates as potential antisense agents. FEBS Lett 456: 59-62 (1999).
34. P. C. de Smidt, T. Le Doan, S. de Falco, and T. J. van Berkel. Association of antisense nucleotides with lipoproteins prolongs the plasma half-life and modifies tissue distribution. Nucleic Acids Res 19: 4695-4700 (1991).
35. E. Vives, P. Brodin, and B. Lebleu. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-7 (1997).
36. G. A. Pietersz, W. Li, and V. Apostolopoulos. A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway. Vaccine 19: 1397-405 (2001).
37. J. B. Rothbard, S. Garlington, Q. Lin, T. Kirschberg, E. Kreider, P. L. McGrane, P. A. Wender, and P. A. Khavari, Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6: 1253-7 (2000).
38. J. B. Rothbard, E. Kreider, C. L. VanDeusen, L. Wright, B. L. Wylie, and P. A. Wender. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 45: 3612-8 (2002).
39. N. Pagratis, M. Lochrie, and L. Gold. High affinity TGFb nucleic acid ligands and inhibitors, Gilead Sciences, Inc., USA, 2002.
40. M. J. Graham, S. M. Freier, R. M. Crooke, D. J. Ecker, R. N. Maslova, and E. A. Lesnik. Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res 21: 3737-43 (1993).
41. S. Uemura, J. B. Rothbard, H. Matsushita, P. S. Tsao, C. G. Fathman, and J. P. Cooke. Short polymers of arginine rapidly translocate into vascular cells: effects on nitric oxide synthesis. Circ J 66: 1155-60 (2002).
42. B. Tavitian, S. Terrazzino, B. Kuhnast, S. Marzabal, O. Stettler, F. Dolle, J. R. Deverre, A. Jobert, F. Hinnen, B. Bendriem, C. Crouzel, and L. Di Giamberardino. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 4: 467-71 (1998).
43. C. M. Smith and J. A. Steitz. Sno storm in the nucleolus: new roles for myriad small RNPs. Cell 89: 669-72 (1997).
44. F. C. Richardson, R. D. Kuchta, A. Mazurkiewicz, and K. A. Richardson. Polymerization of 2′-fluoro- and 2′-O-methyl-dNTPs by human DNA polymerase alpha, polymerase gamma, and primase. Biochem Pharmacol 59: 1045-52 (2000).
45. F. C. Richardson, C. Zhang, S. R. Lehrman, H. Koc, J. A. Swenberg, K. A. Richardson, and R. A. Bendele. Quantification of 2′-fluoro-2′- deoxyuridine and 2′-fluoro-2′-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. Chem Res Toxicol 15: 922-6 (2002).
46. R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296: 890-7 (2001).